A Descriptive Analysis from VigiAccess on Drug-related ProblemsAssociated with the Glucagon-like Peptide-1 Receptor Agonists
Qualified healthcare practitioners must educate the patients administering the GLP- 1 RAs to minimize preventable DRPs. Also, careful and frequent monitoring of GLP-1 RAs improves therapeutic outcomes by ruling out DRPs. Healthcare practitioners should comply with approved therapeutic guidelines to enhance the quality of GLP-1 RAs treatment.
Authors
- Palanisamy Amirthalingam (ORCID: https://orcid.org/0000-0002-5803-1227)
Institutions
- University of Tabuk (SA)
Publication Details
- Journal
- Current Drug Safety
- Published
- 2025-05-07
- DOI
- https://doi.org/10.2174/0115748863367086250420011411
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29